BFA Law probes IBM after $68 billion wipeout on Z shortfall
BFA Law joins Pomerantz LLP in probing IBM for potential securities fraud following a significant stock decline driven by shortfalls in its IBM Z business and failed large deals in Q2FY26.

*this image is generated using AI for illustrative purposes only.
Bleichmar Fonti & Auld LLP has launched an investigation into International Business Machines Corporation (IBM) for potential securities fraud, joining a growing legal scrutiny following the company’s $68 billion market capitalization wipeout on July 14, 2026. The probe targets whether IBM and its officers misled investors regarding the performance of its flagship IBM Z mainframe business, which suffered a significant shortfall in second-quarter 2026 results, contradicting earlier management assurances of robust growth and triggering a 25.21% plunge in share price. Investors who purchased shares during the relevant period are urged to contact the firm to submit their losses.
Investigation Scope
The inquiry by Bleichmar Fonti & Auld LLP (BFA), announced on August 7, 2026, focuses on misrepresentations about the pace of securing new business deals and the strength of the IBM Z product outlook. On July 14, 2026, IBM reported that numerous large deals failed to close on expected timelines due to the company’s failure to "adapt and move quickly enough," primarily impacting Transaction Processing revenues. CEO Arvind Krishna attributed the miss to customer capital expenditure reprioritization. The stock fell $73.16 per share to close at $217.07 on that day. BFA is examining if material non-public information regarding these deal slippages was withheld from investors prior to public disclosure.
This investigation runs parallel to a separate probe by Pomerantz LLP, announced on August 6, 2026, which cited similar concerns about management’s statements made as early as April 22, 2026. At that time, executives had described the start of the year as a "record start" for the z17 product, with IBM Z revenues rising 51% in Q1FY26. Other firms, including Glancy Prongay Wolke & Rotter LLP and Levi & Korsinsky LLP, are also scrutinizing IBM’s disclosures.
Financial Divergence
The gap between IBM’s optimistic April guidance and the July actuals highlights severe volatility in its enterprise software cycles. While generative AI accounted for approximately 50% of signings in Q2FY26, it failed to offset the decline in traditional transaction processing revenues. The disparity underscores the company’s exposure to large-deal timing risks within the Transaction Processing segment.
| Metric | April 2026 Guidance/Report | July 2026 Actuals |
|---|---|---|
| Total Revenue Growth | 5-plus percent projected | +1% |
| Infrastructure Revenue | +15% (Q1) | -7% |
| IBM Z Revenue | +51% (Q1) | Shortfall reported |
| Market Value Impact | N/A | -$68 billion |
What the Numbers Show
The concentration risk within IBM’s Transaction Processing segment remains a critical vulnerability. The sharp reversal from 51% growth in Q1 to a reported shortfall in Q2 illustrates the fragility of forward-looking statements when dependent on large, discrete deals. Although management frames the issue as deferral rather than destruction, expecting two-thirds to three-quarters of slipped deals to close within six months, the immediate market reaction reflects deep skepticism about the reliability of such projections amidst shifting customer priorities.
How might the consolidation of multiple securities fraud investigations impact IBM's ability to secure favorable settlement terms or influence its future corporate governance reforms?
Will the market's skepticism regarding deferred large deals lead to a sustained re-rating of IBM's valuation multiples, or is the current price drop viewed as a temporary overreaction?
To what extent will the reliance on generative AI signings fail to fully offset the structural decline in traditional Transaction Processing revenues in the coming fiscal quarters?






























